

Edgar Filing: AVOCENT CORP - Form 8-K

AVOCENT CORP  
Form 8-K  
May 02, 2006

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 2, 2006

AVOCENT CORPORATION

(Exact name of registrant as specified in its charter)

|   |                             |                                      |
|---|-----------------------------|--------------------------------------|
| DELAWARE  | 000-30575                   | 91-2032368                           |
| (State or other jurisdiction<br>of incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |

|  |                |       |
|--|----------------|-------|
| 4991 CORPORATE DRIVE                     | HUNTSVILLE, AL | 35805 |
| (Address of principal executive offices) | (Zip Code)     |       |

Registrant's telephone number, including area code (256) 430-4000

n/a

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: AVOCENT CORP - Form 8-K

Item 7.01 Regulation FD Disclosure.

On May 2, 2006, Avocent Corporation prepared a list of answers to frequently asked questions received from its investors regarding its acquisition of Cyclades Corporation and its proposed acquisition of LANDesk Group Limited. The prepared list of frequently asked questions and responses is incorporated herein by reference and furnished as Exhibit 99.13 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit Number | Description of Exhibit                                    |
|----------------|---|
| 99.13          | Frequently asked questions regarding Cyclades and LANDesk |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AVOCENT CORPORATION

Date: May 2, 2006

By: /s/ Edward H. Blankenship

-----  
Edward H. Blankenship  
Senior Vice President of Finance and  
Chief Financial Officer

EXHIBIT INDEX

| Exhibit | Description   |
|---------|---|
| 99.13   | Frequently asked questions regarding Cyclades and LANDesk |